# A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

> **NCT00847613** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 800 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** CP-690,550
- **DRUG:** CP-690,550
- **DRUG:** CP-690,550
- **DRUG:** CP-690,550
- **DRUG:** Placebo
- **DRUG:** CP-690,550
- **DRUG:** Placebo
- **DRUG:** CP-690,550

## Key facts

- **NCT ID:** NCT00847613
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-04
- **Final completion:** 2012-02
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00847613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00847613, "A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00847613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*